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Stroke is the third cause of mortality and the fi  rst 
cause of serious disability in developed countries. 
Genetic research may be helpful to achieve a 
better understanding of susceptibility factors re-
lated to stroke as well as to determine stroke out-
come and even therapeutic responses. Glutamate 
is the main excitatory neurotransmitter in the 
mammalian central system. However, excessive 
levels of extracellular glutamate are excitotoxic 
and lead to neuronal death (for review see refer-
ences 1, 2). Cerebral ischemia results in a de-
crease of oxygen and glucose that is in turn 
responsible for the release of glutamate at the 
presynaptic level. The subsequent activation of 
glutamatergic postsynaptic receptors is the pri-
mary process of a cascade of sequential molecular 
events that   fi  nally result in the death of neurons 
located both adjacent to and distant from the 
  initial necrotic zone. In humans, the concentra-
tions of glutamate in plasma and   cerebrospinal 
fl  uid (CSF) have been found to be signifi  cantly 
higher in patients with large cerebral infarcts, 
and in those with a higher risk of early neuro-
logical deterioration, supporting the excitotoxic 
activity of glutamate in patients with cerebral in-
farction (3, 4). Interestingly, glutamate levels did 
not correlate to the initial stroke severity, and 
their association with progressing stroke was 
  independent of the infarct volume, generating 
the hypothesis of an individual   susceptibility to 
the glutamate-mediated ischemic injury.
Glutamate transport is the primary and only 
mechanism for maintaining extracellular gluta-
mate concentrations below excitotoxic levels 
(for review see references 5–7). This trans-
port is executed by the fi  ve high affi   nity, so-
dium-dependent plasma membrane glutamate 
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It remains unclear why some individuals are susceptible to excitotoxicity after stroke. 
A possible explanation is impaired glutamate uptake. We have found a highly prevalent 
polymorphism in the promoter of the glutamate transporter EAAT2 gene that abolishes 
a putative regulatory site for activator protein–2 (AP-2) and creates a new consensus 
binding site for the repressor transcription factor GC-binding factor 2 (GCF2). The mutant 
genotype is associated with increased plasma glutamate concentrations and with a higher 
frequency of early neurological worsening in human stroke. After transfection into 
  astrocytes, the mutant promoter was not activated by AP-2 and was effectively repressed 
by GCF2, and its activity in the presence of GCF2 was reduced when compared with the 
AP-2–cotransfected wild-type promoter. We also show that GCF2 is expressed in ischemic 
rat brain, suggesting that decreased glutamate uptake occurs in individuals carrying the 
mutation after stroke. These fi  ndings may explain individual susceptibility to excitotoxic 
damage after stroke as well as the failure of glutamate antagonists in those patients 
without this polymorphism.
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transporter subtypes that have been identifi  ed thus far (for 
  review see reference 8). Among them, the astroglial trans-
porter EAAT2 (GLT-1) (9, 10), also found in some neurons, 
is responsible for up to 90% of all glutamate transport in adult 
tissue (for review see reference 11). Recently, the human 
EAAT2 gene promoter has been isolated and characterized, 
and an elevated expression of the gene has been demonstrated 
in astrocytes (12). Bioinformatics analysis of the promoter re-
gion has revealed several potential regulatory transcription 
factor-binding elements, including Sp1, NF-κB, N-myc, 
and NFAT that may contribute to EAAT2 expression and 
its regulation. Polymorphisms in this region could aff  ect or 
create novel regulatory transcription factor-binding elements, 
which could be responsible for diff  erences in both gene func-
tion and regulation under normal and pathological conditions 
such as cerebral ischemia.
The primary aim of this study was to investigate the pres-
ence of functional polymorphisms in the EAAT2 gene that 
could be associated with increased glutamate concentrations 
in blood and neurological deterioration in patients with acute 
ischemic stroke.
RESULTS
Polymorphism analysis
Molecular analysis of the EAAT2 promoter in the total of 
207 individuals (101 patients and 106 controls) allowed the 
detection of a novel polymorphism. The polymorphism was 
an A-to-C change at 181 bp from the   transcriptional start site 
Figure 1.  A polymorphism in the promoter region of the EAAT2 
gene, consisting of an A-to-C change at −181 bp from the 
transcriptional start site. (A) SSCP analysis and complementary
sequence of EAAT2 promoter. (B) Bioinformatic approach of wild 
type and mutant promoters. WT promoter contains a consensus 
  binding site for AP-2 transcription factor (yellow). The polymorphism 
abolishes this sequence and creates a new GCF2 consensus binding 
site (green). The sequence of the primers used in fragment 
  amplification are underlined. WT, wild type; HM, homozygous; 
HT, heterozygous.JEM VOL. 203, March 20, 2006  713
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(Fig. 1 A). The prevalence of the polymorphism in stroke 
  patients was comparable to that of the healthy   subjects (0.43 
vs. 0.39; P = 0.4). Sequence analysis of the promoter region 
revealed that the sequence containing the polymorphism site 
corresponds to the putative regulatory transcription factor-
binding element activator protein–2 (AP-2). The polymor-
phism abolishes this sequence and   creates a new consensus 
sequence corresponding to the   transcription factor-binding 
element GC-binding factor 2 (GCF2) (Fig. 1 B).
Genotype–phenotype correlation
No signifi  cant  diff   erences were found in baseline clinical 
characteristics between patients with wild and mutant geno-
type (Table I). Patients with mutant allele C showed higher 
glutamate concentrations on admission (P = 0.024) and at 
24 h (P = 0.015) (Fig. 2). In agreement with the higher fre-
quency of glutamate levels, >200 μmol/L in   patients with 
  allele C (22.2 vs. 3.4%; Fisher’s exact test; P = 0.017) early 
neurological deterioration (defi  ned as an   increase ≥4 points 
in the National Institutes of Health stroke scale (NIHSS) 
score between admission and 72 h; reference 13) occurred 
more frequently in the mutant group than in the wild-type 
group (23.6 vs. 6.9%; Fisher’s exact test; P = 0.042) (Fig. 3).
Activity and regulation of human EAAT2 promoter 
transfected into rat astrocytes
Rat astrocytes were transfected with either wild-type or mu-
tant pEAAT2PrLUC (plasmid −742/+31, MluI–BglII frag-
ment; cloned into the pGL3-basic vector). In these cells, the 
mutant construct showed a reduction of 30% in promoter 
activity in comparison with the wild type (P < 0.001; Fig. 4, 
control). After cotransfection with AP-2, wild-type but not 
mutant pEAAT2PrLUC activity was increased (Fig. 4; 29% 
increase; P = 0.01). Conversely, mutant but not wild-type 
pEAAT2PrLUC activity was decreased after cotransfection 
with GCF2 (Fig. 4; 57% reduction with regard to the   wild-type 
promoter activity; P < 0.001). Collectively, GCF- cotransfected 
mutant showed a reduction in promoter activity of almost 
70% when compared with AP-2–cotransfected wild-type 
(Fig. 4; P < 0.001).
GCF2 expression in normal and ischemic rat brain
The expression of GCF2 was not detected in either cortex or 
striatum from control rats. However, middle cerebral artery 
occlusion (MCAO) caused the expression of GCF2, which 
was detectable 2 h after the occlusion and persisted 24 h after 
in both cortex and striatum (Fig. 5).
D  I  S  C  U  S  S  I  O  N 
This study has found a novel and highly prevalent polymor-
phism in the promoter of the EAAT2 glutamate transporter 
gene. This polymorphism is not associated with increased risk 
for stroke because its prevalence is comparable in stroke pa-
tients and in healthy subjects. However, this polymorphism 
was associated with higher and maintained plasma glutamate 
concentrations as well as with higher frequency of neuro-
logical deterioration in patients with acute hemispheric 
stroke. Importantly, patients with the mutant genotype had 
a sixfold increase in the risk of having glutamate levels >200 
μmol/L, a threshold that has been associated with neuro-
logical worsening (4). These fi  ndings were not explained by 
diff  erences in the risk factors, baseline characteristics, stroke 
severity, or diff  usion-weighted MRI and perfusion-weighted 
MRI   lesion volumes on admission that were comparable be-
tween the two groups.
Our results support the hypothesis that, in patients with 
acute ischemic stroke, the magnitude of the excitotoxic dam-
age could be genetically determined as the result of a decrease 
in the glutamate uptake. In this context, it has been reported 
that plasma and CSF glutamate levels are elevated in patients 
with acute stroke and that they are threefold higher in pa-
tients with subsequent early neurological deterioration than 
in those with stable or improving stroke (3, 4). In addition, 
CSF glutamate levels on admission have been found to re-
main elevated up to 24 h in patients who develop progressing 
stroke in the following 48 h, whereas they drop to the nor-
mal range within the fi  rst 6 h after onset of the ischemia in 
patients without later neurological worsening (14). Because 
the correlation between CSF and plasma values was high, 
glutamate levels in blood were attributed to the result of the 
acute cerebral ischemia. This hypothesis was further demon-
strated in an experimental model after MCAO (15).
To explore further our clinical hypothesis, we used rat 
astrocytes transiently transfected with the mutant EAAT2 
promoter to study whether the polymorphism aff  ects  its 
functional activity. Promoter fragment −742/+31 was cho-
sen based on previous studies where deletion of the most dis-
tal region (–2426 to –703) did not alter EAAT2-Pr activity 
(12). The −742/+31 fragments from both wild-type and 
mutant promoters were cloned into the pGL3-basic luciferase 
reporter vector and defi   ned as pEAAT2PrLUC-wt or 
pEAAT2PrLUC-mt, respectively. We have found that the 
polymorphism identifi  ed in this study accounts on its own for 
a 30% reduction in the basal EAAT2 promoter activity. 
The glutamate transporter EAAT2 (GLT-1), together with 
the glial transporter EAAT1 (GLAST), is responsible for the 
  majority of total glutamate uptake in the brain (for review see 
reference 8). Partial or total deletion of EAAT2/GLT-1 
transporter leads to neuronal degeneration and brain injury 
(16, 17), whereas optimal functioning of EAAT2/GLT-1 
is essential for minimizing neuronal damage after stroke be-
cause cerebral ischemia-induced down-  regulation of EAAT2/
GLT-1 contributes to neuronal death (18, 19). Because a de-
crease in promoter activity would correlate with decreased 
expression of EAAT2 transporter, these   fi  ndings are consis-
tent with greater glutamate concentrations found in patients 
with the mutant genotype.
To explain how the polymorphism aff  ects the EAAT2 
  promoter activity, we performed a bioinformatic approach. 
A novel fi  nding of our study is that the EAAT2 promoter 
  region contains a consensus binding site for the transcrip-
tion factor AP-2. More interestingly, we have found that the 714  A NOVEL EAAT2 POLYMORPHISM INVOLVED IN STROKE WORSENING | Mallolas et al.
  polymorphism abolishes this AP-2 consensus sequence and 
creates a new sequence that corresponds to the consensus 
binding site for the transcription factor GCF2. AP-2 is a reti-
noic acid–  inducible and developmentally regulated activator of 
transcription expressed in developing and adult brain (20–22), 
that mediates transcriptional activation in response to both the 
phorbol-ester- and diacylglycerol-activated protein   kinase C,
and the cAMP-dependent protein kinase A pathway (23). 
  Alternatively, GCF2 is a transcriptional   repressor that decreases 
activity of several genes (24). To study the functionality of the 
polymorphism, the   activity of the mutated promoter was stud-
ied after cotransfection with these transcriptional regulators. 
Again, in all groups, pEAAT2PrLUC-mt activity was lower 
than pEAAT2PrLUC-wt, confi  rming our previous fi  ndings. 
More interestingly, cotransfection with AP-2 caused a signifi  -
cant increase only in pEAAT2PrLUC-wt   activity in agree-
ment with the presence of an AP-2 consensus sequence in the 
wild-type group, but not in the mutant group. In contrast and 
accordingly with the new consensus site created by the polymor-
phism, cotransfection with GCF2 decreased pEAAT2PrLUC 
activity only in the mutant group. In an attempt to study what 
would   theoretically occur in vivo, we compared the activities of 
each promoter after cotransfection with the transcription   factor 
whose binding site it contains (i.e., GCF2-  cotransfected   mutant 
promoter vs. AP-2–cotransfected wild-type promoter). In these 
  circumstances, there was a drastic reduction (almost 70%) in 
Figure 2.  Glutamate levels in patients on admission with mutant 
allele C (mutant) and without (WT). Boxplots show median values 
(horizontal line inside the box), quartiles (box boundaries), and the largest 
and smallest observed values (error bars) of baseline (Glu_0) and 24-h 
(Glu_24) plasma glutamate levels in acute stroke patients.
Figure 3.  Glutamate levels on admission by neurological deterio-
ration in patients with wild type (black squares) and mutant geno-
type (gray triangles). Neurological deterioration in patients with mutant 
allele C was more frequent and glutamate levels were higher compared 
with those of the wild-type genotype.
Table I. Main characteristics of patients on admission
Characteristic Wild-type
genotype
n = 29
Mutant
genotype
n = 72
p-value
Male, % 48.3 55.6 0.32
Age, yr 66.6 (14.6) 70.3 (8.9) 0.12
Admission delay, min 139.8 (87.6) 175.2 (136.6) 0.19
SBP, mmHg 159.9 (29.6) 167.6 (32.1) 0.26
DBP, mmHg 87.8 (17.5) 88.7 (17.5) 0.81
Serum glucose, mg/dL 127.0 (33.7) 136.1 (55.6) 0.41
Body temperature, °C 36.4 (0.6) 36.4 (0.4) 0.68
Fibrinogen, mg/dL 450.4 (115.0) 444.6 (116.4) 0.82
Early CT signs of infarction, % 73.3 84.8 0.28
Lesion volume, cc
  DWI 19.9 (27.0) 23.6 (36.6) 0.62
 PWIa 115.1 (129.4) 108.8 (87.1) 0.80
Stroke subtype, % 0.90
 Cardioembolic 51.7 52.8
 Atherothrombotic 13.8 16.7
 Undetermined 31.0 29.2
 Other 3.4 1.4
NIHSS score 13.9 (5.6) 12.2 (6.0) 0.20
Vascular risk factors, %
 Smoking  habit 44.8 40.3 0.42
  Alcohol intake (>40 mg/d) 20.7 34.7 0.125
 Diabetes  mellitus 10.3 19.4 0.21
 Hypertension 58.6 56.9 0.52
 Hyperlipidemia 31.0 31.9 0.56
  Previous stroke or TIA 20.7 16.7 0.44
  Valvular heart disease 0 6.9 0.17
 Atrial  fi  brillation 32.1 31.4 0.56
  Ischemic heart disease 17.2 5.6 0.074
Variables are expressed as mean ± SD or as a percentage, as appropriate. SBP, 
systolic blood pressure; DBP, diastolic blood pressure; TIA, transient ischemic attack; 
DWI, diffusion weighted MRI; PWI, perfusion weighted MRI; NIHSS, National 
Institutes of Health stroke scale.
aPWI sequences were obtained in 82 patients (23 wild type and 59 mutant 
genotype). The study was not performed in three patients and the images could not 
be evaluated in 16 cases due to artefacts related to patients’ movement.JEM VOL. 203, March 20, 2006  715
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the activity of the mutant promoter. These data confi  rm the 
following: (a) EAAT2 promoter activity is increased by AP-2 
in the wild-type group; (b) the   polymorphism   described in 
our study not only causes the loss of this activating pathway 
but originates a GCF2-mediated inhibitory one; and (c) this 
polymorphism remarkably aff  ects the regulation pattern of ex-
pression of this glutamate transporter.
Western blot has been performed in normal and ischemic 
brain to determine whether this regulatory scheme mediated 
by GCF2 is present in brain, as it would explain and  exacerbate 
the diff  erences observed in patients with mutant and wild-
type genotype with ischemic stroke. Although AP-2 expres-
sion is known to be expressed in both neurons and astrocytes 
(25), GCF2 expression in brain appears to be very low (26). 
Its brain expression after ischemic injury was unknown, but 
previous evidence suggested it may be induced as is the case 
in other settings, such as after mechanical injury of cells in 
culture as well as after balloon injury of rat carotid artery wall 
(27). Indeed, our data show that GCF2 expression, not 
  detectable in normal brain, is remarkably induced after the 
ischemic occlusion. To our knowledge, this is the fi  rst report 
on brain GCF2 expression after ischemia. These fi  ndings 
strongly suggest that the newly created consensus binding site 
for GCF2 is active, thus leading to an active repression of 
EAAT2 expression. These results may be translated into a 
marked impairment of glutamate uptake in patients aff  ected 
by this polymorphism and may explain the diff  erences in glu-
tamate concentrations and clinical outcome in patients with 
mutant and wild-type genotype reported in this study.
This study has several limitations. The size of the patient 
population was rather small, thus hampering the genotype–
phenotype correlation. Second, we cannot rule out that the 
presence of polymorphisms in other genes, such as genes 
  related to proinfl   ammatory molecules, could aff  ect  the 
  progression of the disease and mask the EAAT2 polymor-
phism eff  ect. However, this study also has some strengths. 
Patients were studied prospectively with a comprehensive 
protocol that included advanced multimodal MRI, so we can 
reasonably rule out the infl   uence of diff  erent initial brain 
  injury in our results. Furthermore, glutamate determinations 
were measured sequentially during the fi  rst 3 d, showing that 
the increase was a result of the cerebral ischemia because they 
dropped to the normal range at 72 h.
Impaired glutamate transport is known to induce neuro-
toxicity associated with numerous neurological processes. 
In the case of EAAT2, reductions in its protein expression 
have been described to take place in ischemia (28), temporal 
lobe epilepsy (29), Alzheimer’s disease (30), Huntington’s 
disease (31), and amyotrophic lateral sclerosis (32, 33) among 
others. This highlights the importance of the polymorphism 
  described in this paper not only on stroke outcome, the main 
focus of the present study, but also in other neuropathologies, 
which deserves further study.
In conclusion, this study has revealed a novel functional 
polymorphism in the EAAT2 promoter region and a pattern 
of regulation that decreases promoter activity. This polymor-
phism is associated with higher plasma glutamate levels and a 
clinically relevant trend toward neurological worsening after 
stroke. These fi  ndings may explain the reported failure of 
glutamate antagonists in human stroke and prompt the use of 
pharmacogenetics in future clinical trials with drugs blocking 
or modifying the excitotoxic pathway.
MATERIALS AND METHODS
Clinical study
We prospectively studied 101 patients with a nonlacunar hemispheric 
  ischemic stroke admitted within 12 h from the onset of symptoms. 106 
Figure 4.  Activity of wild-type and mutant EAAT2 promoter con-
structions transfected into cultured rat astrocytes, either alone or 
cotransfected with AP-2 (SPRSV–AP-2) or GCF2 (pGST/GCF2).
Figure 5.  GCF2 protein levels in rat brain cortex (A) and striatum (B) 
from sham-operated rats and 2 and 24 h after permanent   middle 
cerebral artery occlusion. Representative Western blot of fi  ve
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healthy control subjects matched by age, sex, and vascular risk factors and 
who were selected among patients’ partners were also studied. Exclusion 
criteria were unconfi  rmed acute cerebral infarction by MRI, rapid improve-
ment of symptoms by the time of inclusion, known active seizure or seizure 
within 6 h before initiation of study, previous stroke with persistent ipsilat-
eral defi  cits or prior territorial infarction, chronic liver, renal, hematological 
or immunological diseases, uncontrolled diabetes, and infectious disease in 
the 15 d before inclusion. The Ethics Committee (Hospital Universitario 
Josep Trueta) approved the protocol, and the patients or relatives gave 
  informed consent.
At admission, the NIHSS score was evaluated by a certifi  ed neurologist 
and a multiparametric MRI was performed (median time from stroke onset, 
4.0 h [2.5, 6.3]). Patients were treated according to published guidelines 
(34). Early neurological deterioration (END) was defi  ned as an increase ≥4 
points in the NIHSS score between admission and 72 h (13). No patient was 
lost in follow-up.
Glutamate concentrations were determined in all patients by HPLC in 
plasma samples obtained on admission (2.1 h [1.3, 3.3] from onset) at 24 and 
72 h upon arrival, following the method described elsewhere (4). As previ-
ously reported (4), plasma glutamate concentration values of >200 μmol/L 
have the highest sensitivity and specifi  city in predicting progressing stroke.
Polymorphism analysis. Genomic DNA was isolated from peripheral 
blood samples. Polymorphism screening of EAAT2 promoter was performed 
by PCR and single-strand conformation polymorphism (SSCP) analysis (35). 
For patients in which abnormal SSCP patterns were found, PCR products 
were automatically sequenced. Primers used in −181 A/C polymorphism 
fragment amplifi  cation are described in Fig. 1 B.
Experimental study
All procedures conformed to the Committee of Animal Care at the Univer-
sidad Complutense of Madrid according to European Union and Spanish 
rules (86/609/CEE and RD223/88).
Rat astrocyte cultures. Primary astrocyte cultures were prepared from 
neonatal (P0) Wistar rat cortex as described previously (36, 37).
Construction of the plasmid pEAAT2PrLUC. A 773-bp fragment in-
cluding −742/+31 of full-length EAAT2 promoter was amplifi  ed by PCR 
introducing MluI and BglII restriction sites (Fw-MluI: 5′-C  T  A  G  A  C  G  C  G  T  T-
T  C  A  G  C  C  G  C  T  C  G  A  C  T  C  -3′ and Rv-BglII: 5′-A  T  G  A  A  G  A  T  C  T  C  T  T  G  G-
C  G  G  G  G  A  G  C  T  C  -3′). After enzyme digestion and fragment purifi  cation, the 
−742/+31 fragment from wild-type and mutant promoters were fused upstream 
of the fi  refl  y luciferase reporter in pGL3-basic luciferase reporter vector.
Cell transfection and luciferase reporter gene assay. Reporter assays 
were performed on wild-type and mutant EAAT2 promoter constructions 
(pEAAT2PrLUC-wt and pEAAT2PrLUC-mut) using the Dual-Luciferase 
reporter assay system (Promega) with which pRL-thymidine kinase (TK) 
plasmid (Promega), containing the Renilla luciferase gene under control of 
the TK promoter, was cotransfected as an internal control. In some experi-
ments, this vector was cotransfected with the GCF2 and/or AP-2 plasmids. 
The pGST/GCF2 plasmid, containing the GCF2 transcription factor, and the 
SPRSV–AP-2 plasmid, containing the AP-2 transcription factor under the 
control of RSV promoter and enhancer elements, were gifts from A.C. 
Johnson (National Institutes of Health, Bethesda, MD) and T. Williams 
(University of Colorado Health Sciences Center, Denver, CO), respectively. 
Transient transfection of astrocytes was performed as described previously 
(38) using Lipofectamine 2000 (Invitrogen). The activities of control Renilla 
luciferase and fi  refl  y luciferase were measured in triplicate.
Permanent pMCAO in rats. Experiments were performed on male 
  Fischer rats weighing 250–300 g as described previously (39, 40). Rats in 
which the middle cerebral artery was exposed, but not occluded, served as 
sham-operated controls.
Western blot analysis of GCF2 in sham and ischemic rat brain. 
Brain homogenates from ipsilateral cortices and striata obtained from rats 
killed 2 and 24 h after MCAO (40 μg of protein) were loaded and the 
proteins were size separated in 10% SDS-PAGE (90 mA; reference 36). 
Proteins were blotted onto a PVDF membrane (GE Healthcare) and incu-
bated with the specifi  c primary monoclonal antibody against GCF2 (BD 
Transduction Laboratories; 1:250 dilution). Proteins recognized by the an-
tibody were   revealed by ECL kit (GE Healthcare). β-actin was used as 
loading control.
Statistical analyses. Results are expressed as percentages for categorical 
variables and as mean ± standard deviation or median (quartiles) for the 
continuous variables depending on their normal distribution or not. Propor-
tions were compared using the chi-square test or Fisher’s exact test as appro-
priate. Student’s t test or Mann-Whitney test were used to compare 
continuous variables between groups. A p-value of <0.05 was considered as 
statistically signifi  cant. Statistical analysis was performed using the 11.0.0 ver-
sion of SPSS software (SPSS Inc).
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